These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 17303354)

  • 1. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.
    Adi H; Larson I; Stewart PJ
    Int J Pharm; 2007 Jun; 337(1-2):229-38. PubMed ID: 17303354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation.
    Handoko A; Ian L; Peter SJ
    Eur J Pharm Sci; 2009 Feb; 36(2-3):265-74. PubMed ID: 18996188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of agglomeration in the dispersion of salmeterol xinafoate from mixtures for inhalation with differing drug to fine lactose ratios.
    Adi H; Larson I; Chiou H; Young P; Traini D; Stewart P
    J Pharm Sci; 2008 Aug; 97(8):3140-52. PubMed ID: 18023007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation.
    Adi H; Larson I; Chiou H; Young P; Traini D; Stewart P
    Pharm Res; 2006 Nov; 23(11):2556-65. PubMed ID: 16972185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
    Lohrmann M; Kappl M; Butt HJ; Urbanetz NA; Lippold BC
    Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures.
    Islam N; Stewart P; Larson I; Hartley P
    J Pharm Sci; 2004 Apr; 93(4):1030-8. PubMed ID: 14999738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity.
    Das S; Larson I; Young P; Stewart P
    Eur J Pharm Sci; 2009 Jun; 37(3-4):442-50. PubMed ID: 19491036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin.
    Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
    Int J Pharm; 2010 Apr; 389(1-2):74-85. PubMed ID: 20085803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?
    Islam N; Stewart P; Larson I; Hartley P
    Pharm Res; 2004 Mar; 21(3):492-9. PubMed ID: 15070101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate.
    Tee SK; Marriott C; Zeng XM; Martin GP
    Int J Pharm; 2000 Nov; 208(1-2):111-23. PubMed ID: 11064216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of storage relative humidity on the dispersion of salmeterol xinafoate powders for inhalation.
    Das S; Larson I; Young P; Stewart P
    J Pharm Sci; 2009 Mar; 98(3):1015-27. PubMed ID: 18661537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
    Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A
    Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization.
    Murnane D; Marriott C; Martin GP
    Eur J Pharm Biopharm; 2008 May; 69(1):94-105. PubMed ID: 17981448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances.
    Jones MD; Harris H; Hooton JC; Shur J; King GS; Mathoulin CA; Nichol K; Smith TL; Dawson ML; Ferrie AR; Price R
    Eur J Pharm Biopharm; 2008 Jun; 69(2):496-507. PubMed ID: 18191553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO; Molokhia AM; Elsayed MM
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
    Murnane D; Martin GP; Marriott C
    J Pharm Sci; 2009 Feb; 98(2):503-15. PubMed ID: 18506819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.